Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Meridian, ID
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Evergreen Park, IL
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Bethesda, MD
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Springfield, MA
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Springfield, MA
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Detroit, MI
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Pontiac, MI
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Pontiac, MI
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Reno, NV
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Great Neck, NY
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Mineola, NY
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Asheville, NC
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Wilmington, NC
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Orangeburg, SC
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Houston, TX
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
San Antonio, TX
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women
Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women
Status: Enrolling
Updated:  9/25/2017
Center for Integrative Medicine University of Maryland
mi
from
Baltimore, MD
Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women
Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women
Status: Enrolling
Updated: 9/25/2017
Center for Integrative Medicine University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Mattel Children's Hospital at UCLA
mi
from
Los Angeles, CA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Mattel Children's Hospital at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
BMT Program at Northside Hospital
mi
from
Atlanta, GA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
BMT Program at Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
University of Michigan
mi
from
Ann Arbor, MI
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Oregon Health and Science University
mi
from
Portland, OR
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Virginia Commonwealth University, MCV Hospital
mi
from
Richmond, VA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Virginia Commonwealth University, MCV Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated:  9/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)
Status: Enrolling
Updated: 9/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Chicago, IL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Mobile, AL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Little Rock, AR
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Orange, CA
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Sacramento, CA
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
New Haven, CT
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Daytona Beach, FL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Miami, FL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Orlando, FL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Tampa, FL
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated:  9/28/2017
Clinical Research Facility
mi
from
Atlanta, GA
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Status: Enrolling
Updated: 9/28/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials